WO2011065677A3 - 암 치료용 약학 조성물 - Google Patents

암 치료용 약학 조성물 Download PDF

Info

Publication number
WO2011065677A3
WO2011065677A3 PCT/KR2010/007600 KR2010007600W WO2011065677A3 WO 2011065677 A3 WO2011065677 A3 WO 2011065677A3 KR 2010007600 W KR2010007600 W KR 2010007600W WO 2011065677 A3 WO2011065677 A3 WO 2011065677A3
Authority
WO
WIPO (PCT)
Prior art keywords
flj25416 gene
transcript
flj25416
gene
sequence number
Prior art date
Application number
PCT/KR2010/007600
Other languages
English (en)
French (fr)
Other versions
WO2011065677A2 (ko
Inventor
원미선
정경숙
김영주
홍혜경
염영일
윤채옥
오유경
송경빈
이희구
송은영
김영호
김문희
정경은
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Priority to US13/512,583 priority Critical patent/US8846630B2/en
Publication of WO2011065677A2 publication Critical patent/WO2011065677A2/ko
Publication of WO2011065677A3 publication Critical patent/WO2011065677A3/ko
Priority to US14/476,459 priority patent/US9217149B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 서열번호 3, 서열번호 5, 또는 서열번호 7의 FLJ25416 전사체(mRNA) 염기서열에 상보적으로 결합하여 세포 내에서 FLJ25416의 발현을 억제하는 siRNA(small interfering RNA), FLJ25416의 발현을 억제하는 안티센스 RNA(antisense RNA), 및 FLJ25416의 발현을 억제하는 shRNA(short hairpin RNA)를 암호화하는 DNA(Deoxyribonucleic acid) 중에서 선택된 하나 이상을 포함하는 암치료용 약학 조성물을 제공한다. 본 발명의 FLJ25416 전사체(mRNA transcript)의 염기서열에 상보적인 siRNA, 안티센스RNA 및 shRNA는 암세포에 발현되는 것으로 알려진 FLJ25416의 발현을 억제하여 암세포를 사멸시키므로 본 발명의 조성물은 신규한 항암제로 이용될 수 있다.
PCT/KR2010/007600 2009-11-30 2010-11-01 암 치료용 약학 조성물 WO2011065677A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/512,583 US8846630B2 (en) 2009-11-30 2010-11-01 Pharmaceutical composition for treating cancer
US14/476,459 US9217149B2 (en) 2009-11-30 2014-09-03 Pharmaceutical composition for treating cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0116727 2009-11-30
KR1020090116727A KR101168726B1 (ko) 2009-11-30 2009-11-30 암 치료용 약학 조성물

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/512,583 A-371-Of-International US8846630B2 (en) 2009-11-30 2010-11-01 Pharmaceutical composition for treating cancer
US14/476,459 Division US9217149B2 (en) 2009-11-30 2014-09-03 Pharmaceutical composition for treating cancer

Publications (2)

Publication Number Publication Date
WO2011065677A2 WO2011065677A2 (ko) 2011-06-03
WO2011065677A3 true WO2011065677A3 (ko) 2011-11-03

Family

ID=44067041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/007600 WO2011065677A2 (ko) 2009-11-30 2010-11-01 암 치료용 약학 조성물

Country Status (3)

Country Link
US (2) US8846630B2 (ko)
KR (1) KR101168726B1 (ko)
WO (1) WO2011065677A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101168726B1 (ko) 2009-11-30 2012-07-30 한국생명공학연구원 암 치료용 약학 조성물
WO2019022586A2 (ko) * 2017-07-28 2019-01-31 주식회사 레모넥스 간암의 예방 또는 치료용 약학적 조성물
KR102532779B1 (ko) 2017-09-08 2023-05-16 한국생명공학연구원 Ddias 억제제 및 사멸 수용체 리간드를 포함하는 암의 예방 또는 치료용 조성물
CN113215162B (zh) * 2021-06-02 2023-08-22 山西医科大学 降低铝致Aβ1-42表达水平的干扰RNA及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080044909A (ko) * 2005-09-08 2008-05-21 나스텍 파마수티컬 컴퍼니 인코포레이티드 세포 내로 리보핵산의 전달을 위한 약학 조성물
WO2008156012A1 (ja) * 2007-06-20 2008-12-24 National Institute Of Advanced Industrial Science And Technology モータリン siRNAを含む癌治療剤
KR100883471B1 (ko) * 2005-08-17 2009-02-16 (주)바이오니아 siRNA의 세포내 전달을 위한 siRNA와 친수성 고분자 간의접합체 및 그의 제조방법
KR20090060183A (ko) * 2007-12-06 2009-06-11 한국생명공학연구원 Ｆｌｊ２５４１６ 유전자의 신규한 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106567A1 (en) 1999-09-07 2004-06-03 Hagstrom James E. Intravascular delivery of non-viral nucleic acid
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US20060035815A1 (en) 2004-05-04 2006-02-16 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
CN101052717A (zh) 2004-05-11 2007-10-10 α基因株式会社 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
KR20090083804A (ko) 2008-01-30 2009-08-04 한국생명공학연구원 표적 아형 ｍＲＮＡ의 선택적 발현 억제를 위한 ｓｉＲＮＡ서열을 선정하는 방법
KR101051435B1 (ko) 2008-10-22 2011-07-22 한국생명공학연구원 대장암 관련 마커를 이용한 대장암 진단 키트 및 이를 이용한 대장암 진단 방법
KR101168726B1 (ko) 2009-11-30 2012-07-30 한국생명공학연구원 암 치료용 약학 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100883471B1 (ko) * 2005-08-17 2009-02-16 (주)바이오니아 siRNA의 세포내 전달을 위한 siRNA와 친수성 고분자 간의접합체 및 그의 제조방법
KR20080044909A (ko) * 2005-09-08 2008-05-21 나스텍 파마수티컬 컴퍼니 인코포레이티드 세포 내로 리보핵산의 전달을 위한 약학 조성물
WO2008156012A1 (ja) * 2007-06-20 2008-12-24 National Institute Of Advanced Industrial Science And Technology モータリン siRNAを含む癌治療剤
KR20090060183A (ko) * 2007-12-06 2009-06-11 한국생명공학연구원 Ｆｌｊ２５４１６ 유전자의 신규한 용도

Also Published As

Publication number Publication date
KR20110060209A (ko) 2011-06-08
WO2011065677A2 (ko) 2011-06-03
KR101168726B1 (ko) 2012-07-30
US9217149B2 (en) 2015-12-22
US8846630B2 (en) 2014-09-30
US20130028957A1 (en) 2013-01-31
US20140371300A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
CN107106592B (zh) 用于p21基因调节的rna干扰剂
AU2013296321B2 (en) Modified RNAi agents
SG170780A1 (en) Compositions and methods for inhibiting expression of eg5 gene
WO2007091269A3 (en) NOVEL TANDEM siRNAS
AU2008339215A8 (en) Novel siRNA structure for minimizing off-target effects and relaxing saturation of RNAi machinery and the use thereof
WO2009142822A3 (en) 2-f modified rna interference agents
WO2011008730A3 (en) Chemical modification of small hairpin rnas for inhibition of gene expression
NZ592867A (en) Compositions and methods for inhibiting expression of transthyretin
SG171676A1 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
MX355408B (es) Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado.
NZ593618A (en) Gnaq targeted dsrna compositions and methods for inhibiting expression
WO2007056326A3 (en) Compositions and methods for inhibiting expression of nav1.8 gene
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
WO2009111658A3 (en) Compositions and methods for inhibiting expression of eg5 and vegf genes
WO2010006973A3 (en) Compositions and methods for inhibiting expression of tgf-beta receptor genes
WO2011056005A3 (ko) 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도
MX2009008508A (es) Composiciones y m?todos para prevenir el c?ncer con cupredoxinas.
WO2012178033A3 (en) Serpina1 sirnas: compositions of matter and methods of treatment
WO2011056073A3 (en) Novel compounds for modulating neovascularisation and methods of treatment using these compounds
WO2008036638A3 (en) Rnai modulation of scap and therapeutic uses thereof
WO2007137156A3 (en) Rnai modulation of aha and therapeutic uses thereof
JP2021091710A (ja) Ｅｐａｓ１関連疾患を治療するための有機組成物
NZ599998A (en) Supercoiled minicircle dna for gene therapy applications
WO2011081415A3 (ko) c-Met의 발현을 저해하는 siRNA 및 이를 포함하는 항암 조성물
JP2017511694A (ja) マイクロｒｎａ阻害剤を使用するための組成物および方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10833489

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13512583

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 10833489

Country of ref document: EP

Kind code of ref document: A2